DexTech Medical AB DEX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- —
- Day Range
- —–—
- 52-Week Range
- —–—
- Bid/Ask
- — / —
- Market Cap
- —
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
DexTech Medical AB develops candidate medications with applications within urological oncology, for prostate cancer. Its medication candidates include GuaDex, OsteoDex, and SomaDex, among others. The company conducts operations in medical research with the development of new drug candidates mainly in urological oncology, but also other cancer diseases and for non-malignant diseases. The company has a strong clinical base with valuable specialist expertise from research laboratories and manufacturing to clinical oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1
- Website
- https://www.dextechmedical.com
Valuation
|
Metric
|
DEX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.92 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
DEX
|
|---|---|
Quick Ratio | 47.32 |
Current Ratio | 47.32 |
Interest Coverage | — |
Quick Ratio
DEX
Profitability
|
Metric
|
DEX
|
|---|---|
Return on Assets (Normalized) | −13.03% |
Return on Equity (Normalized) | −13.26% |
Return on Invested Capital (Normalized) | −15.55% |
Return on Assets
DEX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dgmrqvymw | Pdgl | $578.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Wfqnxdzqc | Zmpkdg | $101.5 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Cspyhnvfc | Sfdjdh | $98.1 Bil | |
MRNA
| Moderna Inc | Gysyjhclf | Jfhm | $42.2 Bil | |
ARGX
| argenx SE ADR | Kxxmrkvw | Bbx | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Qhhprblq | Nnly | $21.4 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gvmqzgmxp | Wrxlqnp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bqrvrhc | Mnvftn | $15.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qyxcfyrj | Thbnwwr | $12.5 Bil | |
INCY
| Incyte Corp | Sqvstypz | Vgwcr | $11.7 Bil |